Kineta Q2 2023 Earnings Report

Kineta EPS Results

• Actual EPS: -$0.08
• Consensus EPS: -$0.62
• Beat/Miss: Beat by +$0.54
• One Year Ago EPS: N/A

Kineta Revenue Results

• Actual Revenue: $5.16 million
• Expected Revenue: $0.23 million
• Beat/Miss: Beat by +$4.93 million
• YoY Revenue Growth: N/A

Kineta Announcement Details

• Quarter: Q2 2023
• Date: 8/11/2023
• Time: N/A

Kineta (NASDAQ:KA) is a clinical-stage biotechnology company with a focus on developing immunotherapies that transform patients' lives. It focuses on developing potentially differentiated immunotherapies that address the challenges with current cancer therapy. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug. KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, including non-small cell lung, ovarian, renal cell carcinoma, head and neck, renal cell, and colorectal cancers. It is also developing anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells. The company has collaboration and license agreements with MSD International Business GmbH, Genentech, Inc., FAIR Therapeutics B.V., and GigaGen, Inc. Kineta, Inc. is headquartered in Seattle, Washington.